Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683408 · ClinicalTrials.gov registry record · NA
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
A NA study, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 87
- Enrollment target
NCT02683408: Completed NA study, sponsored by Primus Pharmaceuticals.
NCT02683408 is a NA study that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 87 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02683408, a NA study, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
Study Summary
Diosmiplex is a product marketed for the management of diseases due to venous and microvascular dysfunction. Raynaud's phenomenon is a disorder of characterized by spasm of small arteries and impaired microvascular flow. This study will examine the effects of diosmiplex on the frequency and severity of Raynaud's episodes in susceptible people.
Primary Outcome
For each primary and secondary endpoint, the number and percentage of subjects meeting the criterion will be presented by treatment group at Week 4 and Week 8.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT diosmiplex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-07 |
| Phase | NA |
What the finished NCT02683408 record still lists
NCT02683408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02683408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02683408 about?
NCT02683408 is a clinical study titled "Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon". Diosmiplex is a product marketed for the management of diseases due to venous and microvascular dysfunction. Raynaud's phenomenon is a disorder of characterized by spasm of small arteries and impaired microvascular flow. This study will examine the effects of diosmiplex on the frequency and severity...
What is the current status of trial NCT02683408?
This trial is currently completed. It is a NA study. The enrollment target is 87 participants. The study started on 2016-02. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02683408?
The interventions under investigation include: placebo (OTHER), diosmiplex (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02683408?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02683408's enrollment target sits among peer trials
87 974th of 2000 higher than 1,025 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia